SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI CRYPTO is trending amidst strong community enthusiasm, with many proclaiming it the "Face of Base" and actively buying dips. Discussions highlight its potential for a breakout, driven by technical indicators suggesting base-building and increasing volume, as the community anticipates a broader "altcoin season" and continued momentum within the crypto market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Renewed tensions over US tariff threats on European nations, linked to the demand for Greenland, are a major catalyst driving conversations around QQQ. The community is sharply divided, with some anticipating a significant market correction from these escalating trade disputes, while others believe the market's consistent 'buy the dip' strategy will absorb any initial downturn, maintaining its resilience.

Alchemy Pay

Alchemy Pay is trending due to significant developments in its core infrastructure and regulatory compliance, with community discussion focused on its planned Layer 1 Alchemy Chain upgrade and its emphasis on stablecoin payments. Investors are also reacting to its expanding global footprint, highlighted by securing additional U.S. Money Transmitter Licenses and new partnerships that broaden its fiat-crypto on-ramp services. This strategic pivot and growing real-world utility are fueling renewed bullish sentiment among many.

Avio SpA provides aerospace propulsion systems, engine modules and components. It specializes in equipment, stage assembly, composite containers and structures, SRM thermal protections, structural elements, SRM nozzle, functional tests, cryogenic propulsion, upper-stage storable propulsion, feeding systems, and spacecraft propulsion. The company was founded in 1908 and is headquartered in Colleferro, Italy.

Avio S.p.A - ADR

Avio American Depositary Shares

Avio (AVVSY) is drawing significant community interest as a potential value play, with many noting its notably lower valuation multiple compared to US space sector peers despite similar revenue and profitability. The buzz is driven by its strategic expansion, including plans for a major US manufacturing facility for defense propulsion and a growing pipeline of launch contracts.

Axe Compute, Inc. engages in the application of artificial intelligence medicine and the provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Axe Compute Inc.

Predictive Oncology Inc

Predictive Oncology ($POAI), now known as $AGPU, is trending due to its announced pivot to a digital asset treasury strategy focused on Aethir (ATH) tokens, backed by $344 million in private placements. This abrupt shift from AI-driven oncology to a crypto-centric model has sparked intense debate, with some investors anticipating massive gains from the low float and new AI infrastructure focus, while many others express deep skepticism over past dilutions and reverse splits.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending with significant community buzz, driven by its multi-chain presence across Solana, Cronos, and other major networks. Enthusiasts are actively touting its deflationary mechanics and organic, cult-like following, proclaiming it as a standout 'meme coin' with potential for broader market impact. The widespread 'caw caw' chatter underscores a highly engaged and growing investor base.

Avio S.p.A

Avio (AVVOF) is trending due to significant news regarding its strategic expansion into the US market. The establishment of a new US manufacturing facility, set to supply major defense contractors such as Raytheon and Lockheed Martin, is driving community discussion and investor interest. This development is viewed as a substantial catalyst, reinforcing Avio's position within the aerospace and defense sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense market and political discussion surrounding Donald Trump's reported threats of tariffs on European countries regarding Greenland, and his engagement in international affairs. Community sentiment is sharply divided, with some investors seeing these as bold, strategic moves, while others express significant concern about escalating geopolitical tensions and potential economic repercussions. This ongoing debate about his actions keeps the stock highly volatile and a key talking point among market participants.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge Technologies is currently trending due to a mix of recent analyst upgrades, including TD Cowen moving it to Buy, and a new collaboration with Infineon targeting high-efficiency power infrastructure for AI data centers. While some investors see these developments and recent improved earnings as signs of a turnaround, a strong bearish sentiment persists within the community, fueled by concerns over past losses and significant put option activity, creating notable volatility. The broader solar sector's outlook and policy uncertainty continue to contribute to the divided market perspective.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is highly volatile amid escalating geopolitical tensions, including new tariff threats related to Greenland and China, and fears of military action against Iran. The community is actively debating potential market manipulation and a looming Supreme Court decision on tariffs, while many anticipate significant downside risks and prepare for sharp market movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Schwab Fundamental International Equity ETF (FNDF) a Strong ETF Right Now?

Here's Why You Should Build a Global Portfolio With ETFs 

Despite slowing growth, global equities are showing renewed strength. Discover how a globally diversified ETF portfolio can help investors build more balanced, opportunity-ready portfolios.

Should You Look Abroad? Global Equity ETFs to Consider

Stretched U.S. valuations and AI bubble fears have investors looking abroad and are driving interest in international equity and emerging market ETFs.

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?

Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?

Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as the German drugmaker posted a quarterly earnings beat. Retail traders, however, did not appear too shaken.Fourth-quarter revenue fell to 1.19 billion euros ($1.29 billion) from 1.48 billion euros a year earlier — as demand for COVID-19 vaccines shrank — but was better than Wall Street's estimate of 1.09 billion euros.&nbsp;Likewise, Q4 earnings per share (EPS) fell to 1.08 euros from 1.88 euros a year earlier but easily topped a consensus estimate of 0.41 euros.&nbsp;The company said clinical studies for late-stage oncology candidates raised research and development (R&amp;D) expenses by nearly 6%.For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. The bulk of the sales are expected to come in the final quarter of 2025.The outlook factors in stable vaccination trends, Pfizer-related inventory write-downs, revenue from Germany's pandemic preparedness deal, and BioNTech's service businesses.The company anticipates full-year R&amp;D costs rising to 2.6 billion euros to 2.8 billion euros from 2.25 billion euros in 2024, primarily due to late-stage development and commercial readiness in oncology.Following the results, BofA Securities lowered its price target on BioNTech to $143 from $147 but kept a 'Buy' rating on the shares, noting that 2024 COVID-19 revenue was higher than consensus estimates.However, the research firm flagged potential vaccination policy risks in the U.S. and other regions, saying it would monitor trends in 2025 while remaining optimistic about BioNTech's oncology pipeline, which includes over 20 late-stage trials. Multiple data readouts are expected this year and next.On Stocktwits, sentiment for BioNTech ended on a 'bullish' note on Monday amid a 600% spike in message volume, with shares climbing after the closing bell.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BNTX_sentiment_and_message_volume_as_of_March_10_2c73debe23.png" alt="BNTX sentiment and message volume as of March 10.png" width="1316" height="302"><figcaption>BNTX sentiment and message volume as of March 10 | source: Stocktwits</figcaption></figure>Amid some cautiousness over BioNTech's cash burn, optimistic watchers pinned hopes on the company's oncology pipeline and relatively cheap valuation.&nbsp;<stembedurl>https://stocktwits.com/Robert321/message/607415401</stembedurl><stembedurl>https://stocktwits.com/taxplanr/message/607554091</stembedurl>BioNTech trades at a forward enterprise value-to-sales ratio multiple of 2.5, compared to Pfizer's 3.1 and Eli Lilly &amp; Co's 13.1.Shares are down over 8% this year but have gained 15.6% in the past 12 months.BioNTech stock trades 38% below the average price target of $145.54 set by 21 Wall Street analysts. Of these, 12 rate it a 'Buy,' five a 'Strong Buy,' and four a 'Hold,' according to Koyfin data.(1 euro=$1.08)For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

FNDF
Schwab Strategic Trust - Schwab Fundamental International Large Company Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FNDF News

FNDFSchwab Strategic Trust - Schwab Fundamental International Large Company Index ETF